Stable compositions of mrna-loaded lipid nanoparticles and processes of making
OwnerShrirang KARVE, Frank DEROSA +4inventors
InventorsShrirang KARVE, Frank DEROSA, Michael HEARTLEIN, Natalia VARGAS MONTOYA, Priyal PATEL, Ashish SARODE
Life of this patent
Estimating the term…
Abstract
The present invention provides an improved compositions and processes for preparing mRNA-loaded lipid nanoparticles (mRNA-LNPs). In some embodiments, the present invention provides mRNA-LNPs with exceptional stability and is particularly useful in cases where LNPs comprising low or no PEG-modified lipids are desired.
Claims66
A stable composition comprising lipid nanoparticles encapsulating messenger RNA mRNA, wherein the mRNA encodes a protein or a peptide, wherein each of the lipid nanoparticles comprises one or more cationic lipids, one or more non-cationic lipids and less than 0.5% of PEG-modified lipids or PEG, and wherein the lipid nanoparticles encapsulating the mRNA are stable following one or more freeze thaws.
The stable composition of any one of the preceding claims, wherein the lipid nanoparticles encapsulating the mRNA maintains an average diameter within 10% of the original average size following one or more freeze thaw cycles.
The stable composition of any one of the preceding claims, wherein the lipid nanoparticles encapsulating the mRNA maintains an average diameter within 5% of the original average size following one or more freeze thaw cycles.
The stable composition of any one of the preceding claims, wherein the lipid nanoparticles have an mRNA encapsulation efficiency of between about 50% and 99%.
The stable composition of any one of the preceding claims, wherein each of the lipid nanoparticles further comprises a cholesterol-based lipid.
The stable composition of any one of the preceding claims, wherein each of the lipid nanoparticles comprises 0.4% of PEG-modified lipids or less, 0.3% of PEG-modified lipids or less, 0.2% of PEG-modified lipids or less, or 0.1% of PEG-modified lipids or less.
The stable composition of any one of the preceding claims, wherein each of the lipid nanoparticles is substantially free of PEG-modified lipids.
The stable composition of any one of the preceding claims, wherein each of the lipid nanoparticles comprises an amphiphilic block copolymer.
A stable composition comprising lipid nanoparticles encapsulating a messenger RNA (mRNA) that encodes a protein or a peptide, wherein each of the lipid nanoparticles comprises one or more cationic lipids, one or more non-cationic lipids, a poloxamer and is substantially free of PEG-modified lipids or PEG, and wherein the lipid nanoparticles encapsulating the mRNA are stable following one or more freeze thaw cycles.
A stable composition comprising lipid nanoparticles encapsulating a messenger RNA (mRNA) that encodes a protein or a peptide, wherein each of the lipid nanoparticles comprises one or more cationic lipids, one or more non-cationic lipids, a poloxamer and is substantially free of PEG-modified lipids or PEG, and wherein the lipid nanoparticles encapsulating the mRNA generate low to no anti-PEG antibodies, and/or reduce accelerated blood clearance (ABC).
The stable composition of any one of the preceding claims, wherein the lipid nanoparticles have an average size of less than about 200 nm.
The stable composition of any one of the preceding claims, wherein the lipid nanoparticles have a polydispersity index (PDI) of 0.25 or less, 0.2 or less, 0.15 or less, 0.1 or less.
A method for delivery of messenger RNA (mRNA) for in vivo production of a protein or a peptide, comprising administering to a subject a stable composition according to any one of the preceding claims.
A method for delivery of messenger RNA (mRNA) for in vivo production of a protein or a peptide, comprising administering to a subject a stable composition according to any one of the preceding claims, wherein the administering the stable composition does not results in anti-PEG antibodies and/or accelerated blood clearance (ABC) in the subject.
A process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing an mRNA solution and a lipid solution in the presence of a poloxamer.
Dependencies are inferred from the claim text.